(Reuters) -Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses. The drugmaker also forecast third-quarter adjusted earnings per share in the range of $1.74 to $1.78, according to the filing. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: HIGHLIGHTS FROM QUALIFYING FOR INDONESIAN GRAND PRIX OF THE MOTOGP WORLD CHAMPIONSHIP AT…
(Adds comments) TOKYO, Oct 4 (Reuters) - Sanae Takaichi is likely to be Japan's first…
VIDEO SHOWS: HIGHLIGHTS FROM QUALIFYING FOR INDONESIAN GRAND PRIX OF THE MOTOGP WORLD CHAMPIONSHIP AT…
(Revises slug to remove emphasis on Israel ties, adds details) DUBAI, Oct 4 (Reuters) -…
By Erwin Seba, Shivani Tanna, Nicole Jao and Shariq Khan (Reuters) -Chevron's 285,000-barrel-per-day El Segundo…